An interventional study of mobile application in Lymphedema Arm, sponsored by Inonu University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by Inonu University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 400 studies in Breast Neoplasms with a site in Turkey — 83 open to participants now, 129 under way, 46 of them phase 3. Breast Neoplasms · Turkey.
Among the 400 studies in Breast Neoplasms with a site in Turkey, this one is the 146th largest by planned enrollment of the 321 interventional ones that give a count, is one of 45 that started in 2025, is one of 184 with no phase, reaches primary completion later than 77 of the 128 other live ones, and was the 323rd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →83 of the 400 studies in Breast Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:
Pamukkale University · Sites in Turkey
Ages 18+ · Women only · Healthy volunteers
Bursa City Hospital · Sites in Turkey
Ages 18–85 · Women only
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey · Sites in Turkey
Ages 18–65 · Women only
Ege University · Sites in Turkey
Ages 18+ · Women only
Mucahide Emine Fidancı Kuas · Sites in Turkey
Ages 18–85 · Women only · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
400 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 36 · Phase 3 98 · Phase 4 5
First in 1996; this study’s year is marked. 45 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 321 interventional studies, 80 across the 79 observational. Of the 247 that completed or were terminated, 67 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
131 of 400 have an industry lead sponsor. The 10 most frequent:
Inonu University is the lead sponsor of 399 studies on the registry; 98 are open to participants now.
Inonu University has 6 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
34 of the studies in Breast Neoplasms with a site in Turkey that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
Add all 34 to your calendar (.ics) → With an account.
Among the 400 studies in Breast Neoplasms with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Breast cancer is the most common cancer among women in the world and in our country and affects women negatively in many ways. Depending on the treatment, patients experience serious problems. Especially in patients with sentinel lymph node biopsy and axillary lymph node dissection, lymphedema frequently occurs in the postoperative period. Lymphedema can develop at any time after breast cancer surgery and is difficult to treat once it occurs. Lifelong self-management is essential for breast cancer patients to prevent lymphedema and control or delay its progression. In the literature, it has been reported that patients do not have sufficient information about lymphedema, are not aware that they may have lymphedema in the future and do not receive the necessary support. This study aims to determine the effectiveness of mobile technology supported self-management training for the prevention of lymphedema in patients with breast cancer.
The research will be conducted in two stages, methodological and randomized controlled pretest-posttest design. The population of the study will consist of patients diagnosed with breast cancer who have undergone breast surgery at least three months ago at Inonu University Turgut Özal Medical Center Oncology Hospital in Malatya province and who agree to participate in the study. The sample will consist of 147 people in the first stage and 120 people in the second stage, 60 for each group (experimental and control) determined by power analysis. People will be randomly assigned to the experimental and control groups. The research data will be collected using Personal Information Form, Lymphedema Self-Management Support Scale for Breast Cancer Survivors, Breast Cancer Survivorship Self-Efficacy Scale, Rosenberg Self-Esteem Scale. As a result of the research, it will be determined how the mobile application affects the self-management and self-esteem of breast cancer patients. This mobile application developed in line with the results obtained can be recommended to patients with breast cancer.
Breast cancer is a disease in which abnormal breast cells grow out of control and form tumors which, if left uncontrolled, spread throughout the body and can even be fatal. Breast cancer is the most common cancer among women in the world and in our country and affects women physically, psychologically and socially. Local (surgical treatment, radiotherapy) and systemic (chemotherapy, hormone therapy, targeted drug therapy, immunotherapy) methods are used in the treatment of breast cancer. It is usually treated surgically, followed by chemotherapy or radiotherapy or a combination of the two. Patients receiving breast cancer treatment experience serious physical, psychological and social problems depending on the treatment. Especially in patients with sentinel lymph node biopsy and axillary lymph node dissection, lymphedema frequently occurs in the postoperative period.
Lymphedema occurs as a result of primary or secondary lymphatic dysfunction. Primary lymphedema is associated with developmental anomalies of the lymphatic system. Secondary lymphedema, on the other hand, is the type that is frequently encountered and usually seen in the upper extremities after breast cancer treatment approaches. Breast cancer-related lymphedema is a pathologic condition in which protein-rich fluid accumulates in soft tissues due to interruption of lymphatic fluid flow and an increase of 2 cm or more in arm circumference . Breast cancer-related lymphedema is a common complication after treatment. Lymphedema may occur in the arm, trunk or preserved breast . The incidence of lymphedema varies according to the treatment administered, lymphedema diagnostic criteria and follow-up period . In the literature, it is reported that the incidence of lymphedema after breast cancer treatment varies between 24.8% and 90.4% . In long-term prospective studies, it was found that the incidence of lymphedema ranged between 42% in five-year follow-up and 15-54% in three-year follow-up. In the early postoperative period after mastectomy, transient arm edema may occur due to local edema in the surgical field, which does not increase the arm circumference by more than 3 cm. The frequency of transient arm edema is not more than 5%. This is not of much clinical importance and does not require treatment. However, lymphedema may develop months or even years after surgery .Breast cancer-related lymphedema may occur immediately after treatment or may occur years later. Lymphedema formation is related with the degree of axillary dissection. The more lymph nodes are removed, the higher the risk of lymphedema. In the literature, it has been reported that breast cancer-related lymphedema is observed at a higher rate in mastectomy compared to breast conserving surgery.
Breast cancer-related lymphedema, a chronic complication, may develop at any time after breast cancer surgery and is difficult to treat once it occurs. The first stage of treatment consists of decongestive treatment methods such as skin care, manual lymph drainage, compression therapy, and exercises. In the second stage, lifelong self-management is essential for breast cancer patients to prevent lymphedema and control or delay its progression . Self-management is a positive and dynamic process in which a person manages his/her own chronic condition, such as lifestyle changes, symptom control, and treatment adherence. It is used to promote physical and mental health and improve quality of life.
In the literature, it has been reported that breast cancer patients at risk of lymphedema do not have sufficient information about lymphedema and are not aware that they may have lymphedema in the future. However, they also reported that they were not adequately informed about lymphedema before or after surgery. Oncology nurses play a key role in identifying patients with breast cancer at risk of lymphedema, providing comprehensive evaluation and early intervention, coordinating appropriate referrals to interdisciplinary team members for lymphedema management, and supporting patient self-management of lymphedema. However, reasons such as inadequate knowledge of nurses about lymphedema, not considering patient education as their role, lack of specialized nurses in this field, and high workload of nurses may negatively affect lymphedema self-management in breast cancer patients.
Considering all these factors, other opportunities should be offered to patients for lymphedema self-management. Especially in recent years, mobile health-based self-management interventions have become popular with the increase in smartphone use. Mobile health-based self-management interventions have been shown to improve self-management behaviors, functional exercise compliance, self-efficacy, disease-related quality of life, and reduce the incidence of lymphedema and anxiety levels in breast cancer patients. Compared to traditional care, it is emphasized that self-management interventions based on mobile health applications may be more useful in terms of eliminating time and space limitations and may facilitate health care by reaching more people.
Based on this literature, this study aims to determine the effectiveness of mobile technology supported self-management training for the prevention of lymphedema in patients with breast cancer.
Inclusion Criteria:Female patients with primary breast cancer
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
control group
Mobile application
Other: mobile application
mobile application for lymphedema information and exercise
Lymphedema Self-Management Support Scale For Breast Cancer Survivors
The Lymphedema Self-Management Support Scale for Breast Cancer Patients was developed by Fu et al. in 2024 to assess and understand the lymphedema self-management support received by breast cancer survivors. The scale consists of 21 items and 4 sub-dimensions. The 5-point Likert-type scale is scored as 0-not at all, 1-slightly, 2-moderately, 3-much, and 4-more. The total score of the scale is between 0 and 84. The higher the score, the higher the degree of support for lymphedema self-management. The total Cronbach's alpha value of the scale is 0.94 and the sub-dimensions are 0.88 for Basic Management Support, 0.95 for Treatment Management Support, 0.73 for Role Management Support and 0.79 for Emotional Management Support.
Time frame: up to six months
Rosenberg Self-Esteem Scale
This scale was developed by Rosenberg in 1963 to assess self-esteem and its Turkish validity and reliability study was conducted by Çuhadaroğlu in 1986. Consisting of 63 items, the scale has 12 sub-dimensions and it is stated that the sub-dimensions can be used separately. In this study, the first "10" items of the scale will be used to measure self-esteem for the purpose of the research. Guttman scaling technique is used in scale scoring. Questions 1, 2, 4, 6, 7 of the 4-point Likert-type scale are positive and scored from 3 to 0, while questions 3, 5, 8, 9, 10 are negative and scored from 0 to 3. The total score range is between 0-30, with a score below 15 indicating low self-esteem. In Çuhadaroğlu's validity and reliability study, Cronbach's alpha value was found to be 0.71.
Time frame: up to six months
Plan to share: No — To preserve the originality of the work
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Jan 2027, 23 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 23 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.